<ul data-eligibleForWebStory="false"><li>French biotechnology company Ciloa has secured €6.5 million in funding to advance exosome therapy for metabolic diseases.</li><li>The funding will support clinical development of Ciloa's candidate APN-sEV for type 2 diabetes and obesity, as well as large-scale manufacturing under Good Manufacturing Practices.</li><li>Ciloa's unique bioengineering technology has produced stable Adiponectin associated with exosomes (APN-sEV), showing promise in preclinical trials against obesity and diabetes.</li><li>The company plans to begin phase I clinical trials in 2027 and phase IIa in 2028 for its innovative drug composed of adiponectin introduced via small extracellular vesicles.</li></ul>

French scale-up Ciloa raises €6.5 million to advance exosome therapy for metabolic diseases

Discover more